Stocks waver post-Christmas, while precious metals hit new record highs
Seeking Alpha News (Fri, 26-Dec 1:33 PM ET)
Stocks make small moves post-Christmas, while precious metals hit new record highs
Seeking Alpha News (Fri, 26-Dec 10:33 AM ET)
Stocks open little changed while precious metals hit new record highs
Seeking Alpha News (Fri, 26-Dec 9:38 AM ET)
CEPI to Fund Pivotal Phase 3 Trial for Moderna's mRNA Pandemic Influenza Vaccine Candidate
ACCESS Newswire (Thu, 18-Dec 7:00 AM ET)
Moderna to Present at the 44th Annual J.P. Morgan Healthcare Conference
ACCESS Newswire (Wed, 17-Dec 7:00 AM ET)
ACCESS Newswire (Mon, 15-Dec 7:00 AM ET)
Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance
PRNewswire (Fri, 12-Dec 10:48 AM ET)
Global AI Infrastructure Shift Ignites Biotech Growth Phase
Globe Newswire (Tue, 9-Dec 9:25 AM ET)
Moderna Targets 10% Revenue Growth by 2026 with Expanded Vaccine Pipeline and Streamlined Operations
Market Chameleon (Thu, 20-Nov 2:38 AM ET)
Moderna Secures $1.5 Billion Five-Year Credit Facility from Ares Management
ACCESS Newswire (Thu, 20-Nov 7:00 AM ET)
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Moderna trades on the NASDAQ stock market under the symbol MRNA.
As of December 30, 2025, MRNA stock price declined to $30.41 with 5,037,211 million shares trading.
MRNA has a beta of 1.41, meaning it tends to be more sensitive to market movements. MRNA has a correlation of 0.13 to the broad based SPY ETF.
MRNA has a market cap of $11.88 billion. This is considered a Large Cap stock.
Last quarter Moderna reported $1 billion in Revenue and -$.51 earnings per share. This beat revenue expectation by $150 million and exceeded earnings estimates by $1.66.
In the last 3 years, MRNA traded as high as $207.51 and as low as $22.28.
The top ETF exchange traded funds that MRNA belongs to (by Net Assets): VTI, VOO, VB, RSP, IVV.
MRNA has underperformed the market in the last year with a return of -24.2%, while SPY returned +16.7%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in MRNA shares. However, MRNA has outperformed the market in the last 3 month and 2 week periods, returning +20.1% and +1.6%, while SPY returned +3.8% and +1.2%, respectively. This indicates MRNA has been having a stronger performance recently.
MRNA support price is $29.87 and resistance is $32.43 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MRNA shares will trade within this expected range on the day.
